Were Christopher Patusky’s UNITED THERAPEUTICS (UTHR) share sales pre-planned?

Yes. The Form 4 footnote states the stock option exercise and subsequent share sale were made under a Rule 10b5-1 trading plan. This trading plan was entered into on December 18, 2025, indicating the transactions were pre-scheduled rather than discretionary.

United Therapeutics (UTHR) director sells 1,000 shares after option exercise

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

UNITED THERAPEUTICS director Christopher Patusky exercised stock options and sold shares in a planned transaction. He exercised 1,000 stock options at an exercise price of $101.80 per share, then sold 1,000 common shares at $578.88 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he holds 1,490 common shares directly and 1,100 shares indirectly through a trust.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares ($578,880)

Net Sell 4 txns

Insider PATUSKY CHRISTOPHER

Role Director

Sold 1,000 shs ($579K)

Type	Security	Shares	Price	Value
Exercise	Stock Option	1,000	$0.00	--
Exercise	Common Stock	1,000	$101.80	$102K
Sale	Common Stock	1,000	$578.88	$579K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 2,910 shares (Direct); Common Stock — 2,490 shares (Direct); Common Stock — 1,100 shares (Indirect, by Trust)

Footnotes (1)

[object Object]

Key Figures

Options exercised: 1,000 shares Option exercise price: $101.80 per share Shares sold: 1,000 shares +5 more

8 metrics

Options exercised 1,000 shares Stock options converted to common stock on April 17, 2026

Option exercise price $101.80 per share Exercise price of stock options exercised April 17, 2026

Shares sold 1,000 shares Open-market sale of common stock on April 17, 2026

Sale price $578.88 per share Price for open-market sale of 1,000 common shares

Direct holdings after 1,490 shares Common stock directly owned after transactions

Indirect holdings after 1,100 shares Common stock indirectly owned by trust after transactions

Option exercise date June 21, 2017 Original exercise start date of stock options

Option expiration June 21, 2026 Expiration date of stock options exercised

Key Terms

Stock Option, open-market sale, Rule 10b5-1 trading plan, indirect, +1 more

5 terms

Stock Option financial

"security_title": "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1 trading plan regulatory

"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

indirect financial

"ownership_type": "indirect""

by Trust financial

"nature_of_ownership": "by Trust""

Form 4 Insider Transactions: What Each Field Means →

04/17/2026 - 04:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATUSKY CHRISTOPHER

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/17/2026		M⁽¹⁾		1,000	A	$101.8	2,490	D
Common Stock	04/17/2026		S⁽¹⁾		1,000	D	$578.88	1,490	D
Common Stock								1,100	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$101.8	04/17/2026		M⁽¹⁾			1,000	06/21/2017	06/21/2026	Common Stock	1,000	$0.00	2,910	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 18, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did UNITED THERAPEUTICS (UTHR) director Christopher Patusky report?

Christopher Patusky reported exercising 1,000 stock options, then selling 1,000 UNITED THERAPEUTICS common shares. The exercise price was $101.80 per share and the sale price was $578.88 per share, all on April 17, 2026.

How many UNITED THERAPEUTICS (UTHR) shares does Christopher Patusky hold after these transactions?

After the reported transactions, Christopher Patusky holds 1,490 UNITED THERAPEUTICS common shares directly. He also has 1,100 additional shares reported as indirectly owned, held “by Trust,” giving him both direct and indirect ownership positions in the company’s stock.

What prices were involved in Christopher Patusky’s UNITED THERAPEUTICS (UTHR) Form 4 transactions?

The stock options were exercised at an exercise price of $101.80 per share. The 1,000 UNITED THERAPEUTICS common shares acquired from the exercise were then sold at a transaction price of $578.88 per share in an open-market sale on the same date.

What type of securities did Christopher Patusky transact in for UNITED THERAPEUTICS (UTHR)?

He exercised derivative securities described as a “Stock Option” into 1,000 shares of UNITED THERAPEUTICS common stock. He then sold 1,000 shares of that common stock in an open-market transaction, as reflected by the transaction code “S” for sale.